Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients.
Eran KalmanovichPascal BattistellaPhilippe RouviereBernard AlbatJean-Marc FrapierRoland DemariaFabien HuetAudrey AgulloMarc MouradPascal ColsonFlorence LeclercqPhilippe GaudardFrancois RoubillePublished in: Future science OA (2021)
Dabigatran reversal with idarucizumab in contexts of emergency surgery/urgent procedures is an attractive and safe option to be taken into consideration for patients with end stage heart disease awaiting transplantation and indication of anticoagulant therapy.
Keyphrases
- atrial fibrillation
- patients undergoing
- end stage renal disease
- ejection fraction
- minimally invasive
- chronic kidney disease
- newly diagnosed
- public health
- venous thromboembolism
- pulmonary hypertension
- peritoneal dialysis
- coronary artery bypass
- prognostic factors
- cell therapy
- coronary artery disease
- bone marrow
- mesenchymal stem cells
- acute coronary syndrome
- patient reported outcomes
- surgical site infection